Avalyn Publishes Phase 1 Data Supporting Lung-Targeted AP02 In Lung Disease

Avalyn Pharma reported that Respiratory Research published detailed results from two Phase 1 trials of AP02, its nebulized nintedanib formulation, in healthy volunteers and idiopathic pulmonary fibrosis patients. The publication provides clinical validation for the early-stage respiratory therapy, although the article did not disclose efficacy, safety, or financial details likely to materially alter valuation.